Open AccessPrognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor
Author(s) -
Michael J. Cavnar,
Kenneth Seier,
Mithat Gönen,
Christina Curtin,
Vinod P. Balachandran,
William D. Tap,
Cristina R. Antonescu,
S. J. Singer,
Ronald P. DeMatteo
Publication year - 2021
Publication title -
journal of gastrointestinal surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.168
H-Index - 126
eISSN - 1873-4626
pISSN - 1091-255X
DOI - 10.1007/s11605-020-04843-9
Subject(s) - medicine , gist , hazard ratio , imatinib , oncology , clinical endpoint , stromal tumor , univariate analysis , adjuvant therapy , proportional hazards model , primary tumor , imatinib mesylate , gastroenterology , multivariate analysis , stromal cell , cancer , confidence interval , metastasis , clinical trial , myeloid leukemia
Neoadjuvant imatinib (Neo-IM) therapy may facilitate R0 resection in primary gastrointestinal stromal tumors (GISTs) that are large or in difficult anatomic locations. While response to preoperative tyrosine kinase inhibitors is associated with better outcome in metastatic GIST, little is known about prognostic factors after Neo-IM in primary GIST.